The clinical significance of interleukin-1 receptor antagonist +2018 polymorphism in rheumatoid arthritis

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective Interleukin-1 receptor antagonist (IL-1Ra) acts as an inhibitor of IL-1; which is one of the culprit cytokines in rheumatoid arthritis (RA). Although +2018 polymorphism of IL-1Ra has been implicated in the pathogenesis of RA, its importance remains poorly understood. Hence, the purpose of this study was to determine the clinical significance of interleukin-1 receptor antagonist (IL-1Ra) +2018 polymorphism in RA. Methods Polymerase chain reaction (PCR) and sequencing were used to determine the genotypes of the IL-1Ra +2018 for 77 RA patients and 18 healthy controls. All RA patients were assessed for the disease activity score that includes 28 joints (DAS28) and radiographic disease damage based on Modified Sharp Score (MSS). Results The frequency of the T/T and C/T genotypes did not differ significantly (p = 0.893) between the RA patients and the controls. The C/T genotype had significantly higher mean disease activity (DAS 28) and disease damage (MSS) scores with p values of 0.017 and 0.004, respectively. Additionally, the ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), the number of swollen and tender joints were higher for the C/T individuals. On multivariate analysis the CRP, swollen joint count and MSS remained significant with the following p values i.e. 0.045, 0.046 and less than 0.05.Conclusions C/T genotype of IL-1Ra +2018 prognosticates more aggressive disease in RA.

Original languageEnglish
Article numbere0153752
JournalPLoS One
Volume11
Issue number4
DOIs
Publication statusPublished - 1 Apr 2016

Fingerprint

Interleukin-1 Receptors
rheumatoid arthritis
interleukin-1
Polymorphism
antagonists
Rheumatoid Arthritis
genetic polymorphism
receptors
amsonic acid
Genotype
C-Reactive Protein
Joints
genotype
C-reactive protein
Polymerase chain reaction
Interleukin-1
Sedimentation
erythrocyte sedimentation rate
Blood Sedimentation
Cytokines

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

@article{c046bed114374dcab8199ae57ce4224f,
title = "The clinical significance of interleukin-1 receptor antagonist +2018 polymorphism in rheumatoid arthritis",
abstract = "Objective Interleukin-1 receptor antagonist (IL-1Ra) acts as an inhibitor of IL-1; which is one of the culprit cytokines in rheumatoid arthritis (RA). Although +2018 polymorphism of IL-1Ra has been implicated in the pathogenesis of RA, its importance remains poorly understood. Hence, the purpose of this study was to determine the clinical significance of interleukin-1 receptor antagonist (IL-1Ra) +2018 polymorphism in RA. Methods Polymerase chain reaction (PCR) and sequencing were used to determine the genotypes of the IL-1Ra +2018 for 77 RA patients and 18 healthy controls. All RA patients were assessed for the disease activity score that includes 28 joints (DAS28) and radiographic disease damage based on Modified Sharp Score (MSS). Results The frequency of the T/T and C/T genotypes did not differ significantly (p = 0.893) between the RA patients and the controls. The C/T genotype had significantly higher mean disease activity (DAS 28) and disease damage (MSS) scores with p values of 0.017 and 0.004, respectively. Additionally, the ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), the number of swollen and tender joints were higher for the C/T individuals. On multivariate analysis the CRP, swollen joint count and MSS remained significant with the following p values i.e. 0.045, 0.046 and less than 0.05.Conclusions C/T genotype of IL-1Ra +2018 prognosticates more aggressive disease in RA.",
author = "Endom Ismail and Nofal, {Omimah Khaled Jaber} and Sakthiswary Rajalingham and Shaharir, {Syahrul Sazliyana} and Radhika Sridharan",
year = "2016",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0153752",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - The clinical significance of interleukin-1 receptor antagonist +2018 polymorphism in rheumatoid arthritis

AU - Ismail, Endom

AU - Nofal, Omimah Khaled Jaber

AU - Rajalingham, Sakthiswary

AU - Shaharir, Syahrul Sazliyana

AU - Sridharan, Radhika

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Objective Interleukin-1 receptor antagonist (IL-1Ra) acts as an inhibitor of IL-1; which is one of the culprit cytokines in rheumatoid arthritis (RA). Although +2018 polymorphism of IL-1Ra has been implicated in the pathogenesis of RA, its importance remains poorly understood. Hence, the purpose of this study was to determine the clinical significance of interleukin-1 receptor antagonist (IL-1Ra) +2018 polymorphism in RA. Methods Polymerase chain reaction (PCR) and sequencing were used to determine the genotypes of the IL-1Ra +2018 for 77 RA patients and 18 healthy controls. All RA patients were assessed for the disease activity score that includes 28 joints (DAS28) and radiographic disease damage based on Modified Sharp Score (MSS). Results The frequency of the T/T and C/T genotypes did not differ significantly (p = 0.893) between the RA patients and the controls. The C/T genotype had significantly higher mean disease activity (DAS 28) and disease damage (MSS) scores with p values of 0.017 and 0.004, respectively. Additionally, the ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), the number of swollen and tender joints were higher for the C/T individuals. On multivariate analysis the CRP, swollen joint count and MSS remained significant with the following p values i.e. 0.045, 0.046 and less than 0.05.Conclusions C/T genotype of IL-1Ra +2018 prognosticates more aggressive disease in RA.

AB - Objective Interleukin-1 receptor antagonist (IL-1Ra) acts as an inhibitor of IL-1; which is one of the culprit cytokines in rheumatoid arthritis (RA). Although +2018 polymorphism of IL-1Ra has been implicated in the pathogenesis of RA, its importance remains poorly understood. Hence, the purpose of this study was to determine the clinical significance of interleukin-1 receptor antagonist (IL-1Ra) +2018 polymorphism in RA. Methods Polymerase chain reaction (PCR) and sequencing were used to determine the genotypes of the IL-1Ra +2018 for 77 RA patients and 18 healthy controls. All RA patients were assessed for the disease activity score that includes 28 joints (DAS28) and radiographic disease damage based on Modified Sharp Score (MSS). Results The frequency of the T/T and C/T genotypes did not differ significantly (p = 0.893) between the RA patients and the controls. The C/T genotype had significantly higher mean disease activity (DAS 28) and disease damage (MSS) scores with p values of 0.017 and 0.004, respectively. Additionally, the ESR (erythrocyte sedimentation rate), CRP (C-reactive protein), the number of swollen and tender joints were higher for the C/T individuals. On multivariate analysis the CRP, swollen joint count and MSS remained significant with the following p values i.e. 0.045, 0.046 and less than 0.05.Conclusions C/T genotype of IL-1Ra +2018 prognosticates more aggressive disease in RA.

UR - http://www.scopus.com/inward/record.url?scp=84977638117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84977638117&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0153752

DO - 10.1371/journal.pone.0153752

M3 - Article

C2 - 27105431

AN - SCOPUS:84977638117

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0153752

ER -